National Institute of Health Awards SINTX Technologies Phase 1 Grant for SN-PEEK 3D Printed Spinal Implants
September 22 2021 - 9:00AM
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or
the “Company”), an original equipment manufacturer of advanced
ceramics, announced today a Phase 1 grant of $308,301 awarded by
the National Institute of Health (NIH) to develop a 3-D printed,
composite silicon nitride – polyetheretherketone (SN-PEEK) spinal
implant. This U.S. government funded research grant addresses the
antibacterial and osseointegrative properties of silicon nitride
and represents the first NIH grant that has been awarded to SINTX.
Representing approximately 40% of spine implants
within the $10 billion global spine market, PEEK-based spinal
implants are favored because of their long-standing safety and
usability profile. Through the development of 3D printed SN-PEEK
implants, SINTX aims to capitalize on the benefits of PEEK, while
adding the antibacterial and osteoconductive characteristics of
silicon nitride. This will be achieved using modern, cost-effective
3D printing methodologies.
SINTX will be collaborating with Drexel
University, Thomas Jefferson University, and the University of
Pennsylvania School of Veterinary Medicine over the next 9-11
months to design a 3D printed SN-PEEK composite spinal implant that
meets the static loading requirements of the American Society for
Testing and Materials (ASTM), and to characterize its antibacterial
activity, and effect on osteoblast proliferation and maturation.
The NIH grant will support resourcing, acquisition of materials, as
well as testing and trials at SINTX and collaborative universities.
Upon the successful execution of the Phase 1 grant application
goals, SINTX will be well-positioned to seek a Phase 2 award.
“Dr. Steven Kurtz, Dr. Noreen Hickok, and Dr.
Thomas Schaer provided significant contributions to the proposal,
and we are very grateful for their continued support,” said Dr.
Sonny Bal, President, and CEO, SINTX Technologies. “The NIH grant
represents an important milestone in expanding the antibacterial
and osseointegrative properties of silicon nitride into SN-PEEK
composite structures. From a commercial standpoint, this NIH-funded
project is an important step in our strategy to create a new
generation of differentiated spinal implants for prospective
partners.”
Research reported in the “3D Printed Silicon
Nitride Porous PEEK Composite Spinal Cages for Anti-Infection”
proposal was supported by the Department of Health and Human
Sciences of the National Institutes of Health under award number
R41GM146268-01.
The content included in this release is solely
the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of
Health.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes advanced ceramics for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of ceramics for
external partners. The Company presently manufactures silicon
nitride powders and components in its FDA registered, ISO
13485:2016 certified, and ASD9100D certified manufacturing
facility.
For more information on SINTX Technologies
or its silicon nitride material platform, please
visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things: development of SN-PEEK
spinal implant products may take longer than expected and such
products may not prove to be as effective as other products
currently being commercialized or to be commercialized in the
future by competitors; risks inherent in manufacturing and scaling
up to commercial quantities while maintaining quality controls;
volatility in the price of SINTX’s common stock; the uncertainties
inherent in new product development, including the cost and time
required to commercialize such product(s); market acceptance of our
products once commercialized; SINTX’s ability to raise funding and
other competitive developments. Readers are cautioned not to place
undue reliance on the forward-looking statements, which speak only
as of the date on which they are made and reflect management’s
current estimates, projections, expectations and beliefs. There can
be no assurance that any of the anticipated results will occur on a
timely basis or at all due to certain risks and uncertainties, a
discussion of which can be found in SINTX’s Risk Factors disclosure
in its Annual Report on Form 10-K, filed with the Securities and
Exchange Commission (SEC) on March 22, 2021, and in SINTX’s other
filings with the SEC. SINTX disclaims any obligation to update any
forward-looking statements. SINTX undertakes no obligation to
publicly revise or update the forward-looking statements to reflect
events or circumstances that arise after the date of this
report.
Business Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
Media Inquiries for SINTX: Amanda Barry
Director of PR and ContentThe Summit Group abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Aug 2024 to Sep 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Sep 2023 to Sep 2024